Induction of plasminogen activator inhibitor by products released from platelets.
- 1 October 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 82 (4) , 1485-1493
- https://doi.org/10.1161/01.cir.82.4.1485
Abstract
Activation of platelets and augmentation of plasma plasminogen activator inhibitor (PAI) type I activity accompany acute myocardial infarction. To determine whether the two may be related, platelet compounds including epidermal growth factor and transforming growth factor beta as well as platelet lysates were studied in rabbits in vivo. After intravenous infusion of epidermal growth factor (1 and 5 micrograms/kg), plasma PAI activity increased sevenfold and 20-fold, peaking at 2 hours. After infusions of transforming growth factor beta (0.2 and 0.5 microgram/kg), plasma PAI activity increased sevenfold and 12-fold but peaked more slowly (at 5 hours). After infusion of platelet lysates (lysates from 2.8 and 5.6 X 10(8) platelets/kg), the increase was 19-fold and 35-fold, with a peak at 4 hours. Platelet lysates induced a pronounced increase of plasma PAI type 1 messenger RNA (Northern blots) in aorta, liver, and myocardium. Anti-transforming growth factor beta neutralizing antibody markedly attenuated the plasma PAI increase. Concentrations in plasma of fibrinogen and alpha 2-antiplasmin were virtually unaffected under all conditions. Thus, platelet-associated growth factors and platelet lysates, shown previously to increase plasma PAI type 1 messenger RNA expression and protein production in cultured hepatocytes and vascular endothelial cells in vitro, augment plasma PAI in vivo as well. Accordingly, activation of platelets and release of platelet-associated growth factors appear to contribute to the increased plasma PAI seen after myocardial infarction.This publication has 36 references indexed in Scilit:
- Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.Journal of Clinical Investigation, 1989
- Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implicationsThe American Journal of Cardiology, 1989
- Promotion and Subsequent Inhibition of Plasminogen Activation after Administration of Intravenous Endotoxin to Normal SubjectsNew England Journal of Medicine, 1989
- Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA)Thrombosis Research, 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysisJournal of the American College of Cardiology, 1986
- Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells.The Journal of cell biology, 1986
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.Journal of Clinical Investigation, 1983
- A study of proteases and protease-inhibitor complexes in biological fluidsThe Journal of Experimental Medicine, 1978